Dermorphin

Dermorphin is a potent opioid-like peptide originally isolated from amphibian skin secretions. It has been studied primarily as a research tool and has appeared in discussions about experimental analgesia and performance enhancement.

Dermorphin exhibits high affinity for certain opioid receptors, leading to strong analgesic effects in animal models.

Dermorphin is not an approved human medicine in most jurisdictions. Reports of non-regulated use, including in animal sports, have raised significant safety and regulatory concerns.

Lack of standardized formulations and dosing further complicates safety assessment outside research settings.

Dermorphin is a potent mu-opioid agonist, estimated to be 30–40 times more potent than morphine.

Dermorphin is not one molecule but the head of a family. Peptide chemists have produced a large number of variants, "many with superior opioid activity to the original peptide," and forensic laboratories now screen for them as a group — one published equine method covers 17 dermorphin peptides at limits of detection down to 5 pg/mL (Steel et al., Drug Test Anal 2014). Commonly encountered relatives include:

• Hyp6-dermorphin — a naturally occurring variant isolated alongside the parent peptide.
• DALDA and [Dmt1]-DALDA — synthetic tetrapeptide derivatives; [Dmt1]-DALDA was identified in a seized unlabelled vial and detected for the first time in horse urine in a 2024 Hong Kong Jockey Club case report (Choi et al., Drug Test Anal 2024).

This matters for anyone reading a label. A vial marked "dermorphin" may contain a structural analogue with different potency, and the peptides in this family are potent enough that a substitution is not a cosmetic difference. Combining any of them with other central nervous system depressants — alcohol, benzodiazepines, other opioids — compounds respiratory depression risk in the way that opioid combinations generally do.

Research has focused on analgesic potency and receptor pharmacology, mainly in preclinical models. There is little high-quality clinical evidence for therapeutic use.

For deeper dives on this peptide, see:

• Dermorphin benefits and areas of interest
• Dermorphin side effects and safety context
• Dermorphin dosing concepts (educational)
• Dermorphin research and evidence overview

How much more potent than morphine is dermorphin? It depends entirely on the assay, and the commonly quoted "30 to 40 times" is the lowest of the published figures. In the original pharmacology, dermorphin was 39 times more potent than morphine at guinea-pig ileum opiate receptors and about 40 times more potent on the vas deferens preparation — but given directly into the brain of rats it produced analgesia at an ED50 of 13 to 23 pmol per animal, where morphine was 752 to 2,170 times less potent depending on the test (Broccardo et al., Br J Pharmacol 1981). Any single potency multiplier quoted without its assay is meaningless.

Where does dermorphin come from, and why is its structure unusual? It was isolated from methanol extracts of the skin of the South American frog Phyllomedusa sauvagei. It is a heptapeptide, H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, and it was a genuine surprise: a peptide from a vertebrate containing a D-amino acid residue (Montecucchi et al., Int J Pept Protein Res 1981). That D-alanine at position 2 is not decorative — removing it abolishes activity, and the N-terminal tetrapeptide is the minimum sequence for full effect (Broccardo 1981).

What is the "frog juice" horse-racing story? "Frog juice" is the nickname the press attached to dermorphin after a wave of post-race positives in US quarter-horse racing around 2012. The peer-reviewed record is unambiguous about the substance of it: dermorphin was classified as a Class I drug by Racing Commissioners International, and laboratories built dedicated assays specifically "to enforce this ban" (Wang et al., Drug Test Anal 2014); a second group noted that "illicit use of the Dermorphin peptide in the racing industry has shown the need for an analytical method" (Steel et al. 2014); and a University of Pennsylvania pharmacology group recorded that dermorphin "has been identified in postrace horse samples" (Robinson et al., J Vet Pharmacol Ther 2015). Dermorphin's documented modern history is a doping-control history.

What actually happens when a horse is given it? Ten horses received about 9.3 mcg/kg intravenously or intramuscularly. The intravenous route produced excitation and an increased heart rate that subsided after five minutes; the elimination half-life was roughly 46 minutes; and dermorphin remained detectable in plasma for 12 hours and in urine for 48 to 72 hours (Robinson 2015). Those are microgram-per-kilogram doses producing measurable central effects — a useful sense of the scale involved.

Does tolerance and dependence develop? Yes. Continuous intracerebroventricular infusion in rats produced tolerance and naloxone-precipitated withdrawal. The original authors added that both tolerance and physical dependence were "consistently less marked with dermorphin than with morphine" (Broccardo 1981) — a comparative animal observation from 1981 that marketing copy sometimes converts into a claim that dermorphin is non-addictive. It does not support that.

Why is dermorphin not a wellness or recovery compound? Because it is a mu-opioid agonist and nothing about its pharmacology is separable from that. It has no approved human indication in any jurisdiction, no registered clinical trial on ClinicalTrials.gov, and no established human dose. The compounds it belongs with are opioid analgesics carrying respiratory-depression risk — not peptides studied for tissue repair or metabolism. Its appearance in research-chemical catalogues alongside recovery peptides is a categorisation error with real consequences.